Kamada Ltd. (KMDA) Shares Gap Up to $4.20
Kamada Ltd. (NASDAQ:KMDA) shares gapped up prior to trading on Friday . The stock had previously closed at $4.18, but opened at $4.20. Kamada shares last traded at $4.30, with a volume of 11,300 shares trading hands.
A number of research analysts have recently commented on the stock. Zacks Investment Research raised shares of Kamada from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Thursday, May 12th. TheStreet raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, April 25th.
The company’s market capitalization is $154.78 million. The company’s 50-day moving average price is $3.96 and its 200-day moving average price is $3.84.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $18.50 million. On average, analysts forecast that Kamada Ltd. will post ($0.11) earnings per share for the current year.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.